Aligos Therapeutics (5WK0) Financial Statements
Aligos Therapeutics Financial Overview
Aligos Therapeutics's market cap is currently $26.80M. The company's EPS TTM is $-7.30; its P/E ratio is -0.63; Aligos Therapeutics has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 2.19M | $ 3.94M | $ 15.53M | $ 13.91M | $ 4.36M |
| Gross Profit | $ 1.26M | $ 3.94M | $ 15.53M | $ 13.91M | $ 4.36M |
| Operating Income | $ -87.98M | $ -89.15M | $ -88.13M | $ -97.58M | $ -128.32M |
| EBITDA | $ -22.95M | $ -128.26M | $ -83.81M | $ -92.27M | $ -124.41M |
| Net Income | $ -24.19M | $ -131.21M | $ -87.68M | $ -96.05M | $ -128.33M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 77.84M | $ 56.94M | $ 135.70M | $ 125.83M | $ 190.73M |
| Total Assets | $ 88.53M | $ 70.09M | $ 151.53M | $ 146.69M | $ 235.37M |
| Total Debt | $ 5.25M | $ 8.38M | $ 11.14M | $ 12.57M | $ 14.46M |
| Net Debt | $ -13.05M | $ -28.62M | $ -124.57M | $ -68.77M | $ -172.36M |
| Total Liabilities | $ 34.99M | $ 99.07M | $ 59.45M | $ 42.79M | $ 50.64M |
| Stockholders' Equity | $ 53.55M | $ -28.97M | $ 92.08M | $ 103.90M | $ 184.73M |
| Cash Flow | |||||
| Free Cash Flow | $ -82.94M | $ -80.87M | $ -79.02M | $ -80.33M | $ -116.55M |
| Operating Cash Flow | $ -82.50M | $ -80.74M | $ -79.00M | $ -79.39M | $ -115.66M |
| Investing Cash Flow | $ -37.83M | $ -18.28M | $ 44.98M | $ -26.29M | $ 3.02M |
| Financing Cash Flow | $ 101.64M | $ 355.00K | $ 88.33M | $ 164.00K | $ 78.68M |
Currency in USD
